Inogen (INGN) Competitors $7.99 +0.03 (+0.38%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$8.00 +0.00 (+0.06%) As of 08/29/2025 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INGN vs. TNDM, BBNX, SIBN, AXGN, BVS, AVNS, ZIMV, KIDS, TMCI, and SMLRShould you be buying Inogen stock or one of its competitors? The main competitors of Inogen include Tandem Diabetes Care (TNDM), Beta Bionics (BBNX), SiBone (SIBN), AxoGen (AXGN), Bioventus (BVS), Avanos Medical (AVNS), ZimVie (ZIMV), OrthoPediatrics (KIDS), Treace Medical Concepts (TMCI), and Semler Scientific (SMLR). These companies are all part of the "medical equipment" industry. Inogen vs. Its Competitors Tandem Diabetes Care Beta Bionics SiBone AxoGen Bioventus Avanos Medical ZimVie OrthoPediatrics Treace Medical Concepts Semler Scientific Inogen (NASDAQ:INGN) and Tandem Diabetes Care (NASDAQ:TNDM) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment. Which has stronger earnings and valuation, INGN or TNDM? Inogen has higher earnings, but lower revenue than Tandem Diabetes Care. Inogen is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInogen$335.70M0.64-$35.89M-$1.06-7.54Tandem Diabetes Care$940.20M0.90-$96.03M-$3.09-4.05 Does the media favor INGN or TNDM? In the previous week, Tandem Diabetes Care had 3 more articles in the media than Inogen. MarketBeat recorded 6 mentions for Tandem Diabetes Care and 3 mentions for Inogen. Tandem Diabetes Care's average media sentiment score of 1.73 beat Inogen's score of 1.60 indicating that Tandem Diabetes Care is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inogen 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Tandem Diabetes Care 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more risk & volatility, INGN or TNDM? Inogen has a beta of 1.78, indicating that its stock price is 78% more volatile than the S&P 500. Comparatively, Tandem Diabetes Care has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500. Do analysts recommend INGN or TNDM? Inogen presently has a consensus target price of $11.00, indicating a potential upside of 37.67%. Tandem Diabetes Care has a consensus target price of $22.47, indicating a potential upside of 79.59%. Given Tandem Diabetes Care's higher probable upside, analysts plainly believe Tandem Diabetes Care is more favorable than Inogen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inogen 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Tandem Diabetes Care 0 Sell rating(s) 11 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.27 Is INGN or TNDM more profitable? Inogen has a net margin of -7.58% compared to Tandem Diabetes Care's net margin of -20.51%. Inogen's return on equity of -13.77% beat Tandem Diabetes Care's return on equity.Company Net Margins Return on Equity Return on Assets Inogen-7.58% -13.77% -8.52% Tandem Diabetes Care -20.51%-65.40%-13.87% Do insiders and institutionals believe in INGN or TNDM? 89.9% of Inogen shares are owned by institutional investors. 1.5% of Inogen shares are owned by company insiders. Comparatively, 1.9% of Tandem Diabetes Care shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryInogen and Tandem Diabetes Care tied by winning 8 of the 16 factors compared between the two stocks. Get Inogen News Delivered to You Automatically Sign up to receive the latest news and ratings for INGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INGN vs. The Competition Export to ExcelMetricInogenMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$216.05M$7.09B$5.75B$9.76BDividend YieldN/A1.20%4.08%4.04%P/E Ratio-7.5426.1883.2726.60Price / Sales0.64137.43541.17113.73Price / CashN/A21.7237.4459.26Price / Book1.097.0910.556.58Net Income-$35.89M$176.42M$3.27B$265.95M7 Day Performance3.10%0.83%0.40%0.17%1 Month Performance26.62%3.53%7.31%3.90%1 Year Performance-34.88%7.54%46.58%19.67% Inogen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INGNInogen4.2782 of 5 stars$7.99+0.4%$11.00+37.7%-34.9%$216.05M$335.70M-7.541,030News CoveragePositive NewsTNDMTandem Diabetes Care4.5057 of 5 stars$12.11+1.5%$22.47+85.5%-71.2%$818.27M$940.20M-3.922,650Positive NewsBBNXBeta Bionics0.9803 of 5 stars$17.45+2.3%$22.56+29.3%N/A$758.55M$65.12M0.00294News CoverageSIBNSiBone4.3453 of 5 stars$16.05-2.1%$23.67+47.5%+0.3%$692.41M$185.26M-28.66350News CoverageAXGNAxoGen2.4363 of 5 stars$14.79-9.0%$26.00+75.8%+22.7%$680.53M$203.27M-147.89450News CoverageGap DownHigh Trading VolumeBVSBioventusN/A$7.44-2.6%N/AN/A$615.13M$564.14M14.161,200AVNSAvanos Medical3.2718 of 5 stars$11.58-1.2%N/A-50.7%$537.10M$692.50M-1.152,227News CoveragePositive NewsAnalyst RevisionZIMVZimVie0.6004 of 5 stars$18.96+0.1%$17.75-6.4%+8.9%$534.67M$449.75M-27.091,770News CoveragePositive NewsKIDSOrthoPediatrics4.3401 of 5 stars$20.29+0.4%$34.14+68.3%-33.1%$508.75M$220.73M-11.34200TMCITreace Medical Concepts2.2058 of 5 stars$7.47-3.0%$9.83+31.6%+19.0%$471.88M$209.36M-9.46250News CoveragePositive NewsSMLRSemler Scientific3.2356 of 5 stars$30.02-4.5%$81.75+172.3%+11.0%$444.60M$56.29M12.35120News Coverage Related Companies and Tools Related Companies Tandem Diabetes Care Alternatives Beta Bionics Alternatives SiBone Alternatives AxoGen Alternatives Bioventus Alternatives Avanos Medical Alternatives ZimVie Alternatives OrthoPediatrics Alternatives Treace Medical Concepts Alternatives Semler Scientific Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INGN) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inogen, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Inogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INGN Stock Alerts